Annate Bitherapeutics Information

Annate Bitherapeutics is a biotechnology company pioneering a first-in-class bispecific antibody platform that redirects a naturally occurring, immune cell-independent, component of the innate immune system to selectively kill cancer cells. Our lead programs target multiple myeloma and pancreatic ductal adenocarcinoma, with early preclinical studies showing strong efficacy and a favorable safety profile. With exclusive rights to foundational IP and partnerships across leading academic institutions, Annate is advancing toward IND-enabling studies to deliver a new treatment paradigm for patients with limited therapeutic options.